ABL Diagnostics (XPAR:ABLD) Other Stockholders Equity: €0.24 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ABLD ABL Diagnostics XPAR:ABLD
50 GF Score
Price €2.34
GF Value €7.85
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is ABL Diagnostics Other Stockholders Equity?

ABL Diagnostics XPAR:ABLD +0.86% 50 Other Stockholders Equity is €0.24 Mil as of Dec. 2025. GuruFocus rates XPAR:ABLD with a GF Score™ of 50/100 and a GF Value™ of €7.85 (Significantly Undervalued). The stock has 4 warning signs investors should review.

ABL Diagnostics's Other Stockholders Equity for the quarter that ended in Dec. 2025 was €0.24 Mil.

ABL Diagnostics's quarterly Other Stockholders Equity declined from Dec. 2024 (€0.24 Mil) to Jun. 2025 (€0.24 Mil) but then increased from Jun. 2025 (€0.24 Mil) to Dec. 2025 (€0.24 Mil).

ABL Diagnostics's annual Other Stockholders Equity stayed the same from Dec. 2023 (€0.24 Mil) to Dec. 2024 (€0.24 Mil) and stayed the same from Dec. 2024 (€0.24 Mil) to Dec. 2025 (€0.24 Mil).

ABL Diagnostics Other Stockholders Equity Historical Data

* Premium members only.

The historical data trend for ABL Diagnostics's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ABL Diagnostics Other Stockholders Equity Chart

ABL Diagnostics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.24 0.24 0.24 0.24 0.24

ABL Diagnostics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.24 0.24 0.24 0.24
XPAR:ABLD
50GF Score
ABL Diagnostics XPAR:ABLD
Other Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ABL Diagnostics Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

What does a Other Stockholders Equity of €0.24 Mil mean?
ABL Diagnostics (XPAR:ABLD) has a Other Stockholders Equity of €0.24 Mil as of Dec. 2025. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on ABL Diagnostics and its competitors.
Is ABL Diagnostics' Other Stockholders Equity too high?
ABL Diagnostics' current Other Stockholders Equity is €0.24 Mil. Overall, ABL Diagnostics has a GF Score™ of 50/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' Other Stockholders Equity compare to VEEV and BTSG?
ABL Diagnostics' Other Stockholders Equity of €0.24 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Stockholders Equity for a Healthcare Providers & Services company?
A good Other Stockholders Equity depends on the Healthcare Providers & Services industry context. However, Other Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Stockholders Equity mean?
A high Other Stockholders Equity can signal that a stock is expensive relative to its fundamentals. Other Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. View historical data on ABL Diagnostics and its competitors. ABL Diagnostics's current Other Stockholders Equity is €0.24 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.85, compared to a current price of €2.34 — trading 70.2% below its estimated fair value. The current Other Stockholders Equity is €0.24 Mil. ABL Diagnostics' overall GF Score™ is 50/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Stockholders Equity calculated?
Other Stockholders Equity is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current Other Stockholders Equity is €0.24 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?

Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued. The current stock price of €2.34 is trading 70.2% below its estimated GF Value™ of €7.85. GuruFocus considers ABL Diagnostics to be Significantly Undervalued.

Key valuation signals for XPAR:ABLD:

  • Other Stockholders Equity: €0.24 Mil
  • GF Value™: €7.85 vs. price of €2.34 (70.2% below fair value)
  • GF Score™: 50/100 with 4 warning signs

No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ABL Diagnostics Business Description

Other Exchanges 9BK0:Germany
Address 72c, rue de, WOIPPY, Thionville, FRA, 57140
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
50GF Score

Get the complete analysis for XPAR:ABLD

Other Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.34
Price
€7.85
GF Value